Human EGF is a 6-kDa protein with 53 amino acid residues and three intramolecular disulfide bonds. EGF binds to the epidermal growth factor receptor. Initially, human EGF was known as urogastrone.
This report studies the Recombinant Human EGF (Epidermal Growth Factor) obtained by recombinant protein.
麻豆原创 Analysis and Insights: Global Recombinant Human EGF 麻豆原创
The global Recombinant Human EGF market is projected to grow from US$ 11340 million in 2024 to US$ 19500 million by 2030, at a Compound Annual Growth Rate (CAGR) of 9.5% during the forecast period.
EGF acts by binding with high affinity to epidermal growth factor receptor (EGFR) on the cell surface.
This stimulates ligand-induced dimerization, activating the intrinsic protein-tyrosine kinase activity of the receptor.
The tyrosine kinase activity, in turn, initiates a signal transduction cascade that results in a variety of biochemical changes within the cell 鈥� a rise in intracellular calcium levels, increased glycolysis and protein synthesis, and increases in the expression of certain genes including the gene for EGFR 鈥� that ultimately lead to DNA synthesis and cell proliferation.
Report Covers:
This report presents an overview of global market for Recombinant Human EGF market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Recombinant Human EGF, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Recombinant Human EGF, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Recombinant Human EGF revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Recombinant Human EGF market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Recombinant Human EGF revenue, projected growth trends, production technology, application and end-user industry.
麻豆原创 Segmentation
By Company
FUJIFILM Irvine Scientific
PeproTech, Inc
R&D Systems (Bio-Techne)
Miltenyi Biotec
Thermo Fisher Scientific
Abcam PLC
BioLegend Way
STEMCELL Technologies
Eurofins DiscoverX
RayBiotech, Inc
Prospec-Tany
Tonbo Biosciences
EnQuire Bio
ScienCell Research Laboratories
BioVision, Inc
Abm Inc
Cell Guidance Systems
Creative BioMart
Sino Biological
Cell Sciences
Axol Bioscience
Segment by Type
鈮�98% SDS-PAGE
95%-98% SDS-PAGE
<95% SDS-PAGE
Segment by Application
Scientific Research
Medical Drug
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Recombinant Human EGF in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Recombinant Human EGF companies鈥� competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Recombinant Human EGF revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Recombinant Human EGF 麻豆原创 Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 鈮�98% SDS-PAGE
1.2.3 95%-98% SDS-PAGE
1.2.4 <95% SDS-PAGE
1.3 麻豆原创 by Application
1.3.1 Global Recombinant Human EGF 麻豆原创 Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Scientific Research
1.3.3 Medical Drug
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Recombinant Human EGF 麻豆原创 Perspective (2019-2030)
2.2 Global Recombinant Human EGF Growth Trends by Region
2.2.1 Recombinant Human EGF 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Recombinant Human EGF Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Recombinant Human EGF Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Recombinant Human EGF 麻豆原创 Dynamics
2.3.1 Recombinant Human EGF Industry Trends
2.3.2 Recombinant Human EGF 麻豆原创 Drivers
2.3.3 Recombinant Human EGF 麻豆原创 Challenges
2.3.4 Recombinant Human EGF 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Recombinant Human EGF by Players
3.1.1 Global Recombinant Human EGF Revenue by Players (2019-2024)
3.1.2 Global Recombinant Human EGF Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Recombinant Human EGF 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Recombinant Human EGF, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Recombinant Human EGF 麻豆原创 Concentration Ratio
3.4.1 Global Recombinant Human EGF 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Recombinant Human EGF Revenue in 2023
3.5 Global Key Players of Recombinant Human EGF Head office and Area Served
3.6 Global Key Players of Recombinant Human EGF, Product and Application
3.7 Global Key Players of Recombinant Human EGF, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Recombinant Human EGF Breakdown Data by Type
4.1 Global Recombinant Human EGF Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Recombinant Human EGF Forecasted 麻豆原创 Size by Type (2025-2030)
5 Recombinant Human EGF Breakdown Data by Application
5.1 Global Recombinant Human EGF Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Recombinant Human EGF Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Recombinant Human EGF 麻豆原创 Size (2019-2030)
6.2 North America Recombinant Human EGF 麻豆原创 Size by Type
6.2.1 North America Recombinant Human EGF 麻豆原创 Size by Type (2019-2024)
6.2.2 North America Recombinant Human EGF 麻豆原创 Size by Type (2025-2030)
6.2.3 North America Recombinant Human EGF 麻豆原创 Share by Type (2019-2030)
6.3 North America Recombinant Human EGF 麻豆原创 Size by Application
6.3.1 North America Recombinant Human EGF 麻豆原创 Size by Application (2019-2024)
6.3.2 North America Recombinant Human EGF 麻豆原创 Size by Application (2025-2030)
6.3.3 North America Recombinant Human EGF 麻豆原创 Share by Application (2019-2030)
6.4 North America Recombinant Human EGF 麻豆原创 Size by Country
6.4.1 North America Recombinant Human EGF 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Recombinant Human EGF 麻豆原创 Size by Country (2019-2024)
6.4.3 North America Recombinant Human EGF 麻豆原创 Size by Country (2025-2030)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Recombinant Human EGF 麻豆原创 Size (2019-2030)
7.2 Europe Recombinant Human EGF 麻豆原创 Size by Type
7.2.1 Europe Recombinant Human EGF 麻豆原创 Size by Type (2019-2024)
7.2.2 Europe Recombinant Human EGF 麻豆原创 Size by Type (2025-2030)
7.2.3 Europe Recombinant Human EGF 麻豆原创 Share by Type (2019-2030)
7.3 Europe Recombinant Human EGF 麻豆原创 Size by Application
7.3.1 Europe Recombinant Human EGF 麻豆原创 Size by Application (2019-2024)
7.3.2 Europe Recombinant Human EGF 麻豆原创 Size by Application (2025-2030)
7.3.3 Europe Recombinant Human EGF 麻豆原创 Share by Application (2019-2030)
7.4 Europe Recombinant Human EGF 麻豆原创 Size by Country
7.4.1 Europe Recombinant Human EGF 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Recombinant Human EGF 麻豆原创 Size by Country (2019-2024)
7.4.3 Europe Recombinant Human EGF 麻豆原创 Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Recombinant Human EGF 麻豆原创 Size (2019-2030)
8.2 China Recombinant Human EGF 麻豆原创 Size by Type
8.2.1 China Recombinant Human EGF 麻豆原创 Size by Type (2019-2024)
8.2.2 China Recombinant Human EGF 麻豆原创 Size by Type (2025-2030)
8.2.3 China Recombinant Human EGF 麻豆原创 Share by Type (2019-2030)
8.3 China Recombinant Human EGF 麻豆原创 Size by Application
8.3.1 China Recombinant Human EGF 麻豆原创 Size by Application (2019-2024)
8.3.2 China Recombinant Human EGF 麻豆原创 Size by Application (2025-2030)
8.3.3 China Recombinant Human EGF 麻豆原创 Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Recombinant Human EGF 麻豆原创 Size (2019-2030)
9.2 Asia Recombinant Human EGF 麻豆原创 Size by Type
9.2.1 Asia Recombinant Human EGF 麻豆原创 Size by Type (2019-2024)
9.2.2 Asia Recombinant Human EGF 麻豆原创 Size by Type (2025-2030)
9.2.3 Asia Recombinant Human EGF 麻豆原创 Share by Type (2019-2030)
9.3 Asia Recombinant Human EGF 麻豆原创 Size by Application
9.3.1 Asia Recombinant Human EGF 麻豆原创 Size by Application (2019-2024)
9.3.2 Asia Recombinant Human EGF 麻豆原创 Size by Application (2025-2030)
9.3.3 Asia Recombinant Human EGF 麻豆原创 Share by Application (2019-2030)
9.4 Asia Recombinant Human EGF 麻豆原创 Size by Region
9.4.1 Asia Recombinant Human EGF 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Recombinant Human EGF 麻豆原创 Size by Region (2019-2024)
9.4.3 Asia Recombinant Human EGF 麻豆原创 Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Recombinant Human EGF 麻豆原创 Size (2019-2030)
10.2 Middle East, Africa, and Latin America Recombinant Human EGF 麻豆原创 Size by Type
10.2.1 Middle East, Africa, and Latin America Recombinant Human EGF 麻豆原创 Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Recombinant Human EGF 麻豆原创 Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Recombinant Human EGF 麻豆原创 Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Recombinant Human EGF 麻豆原创 Size by Application
10.3.1 Middle East, Africa, and Latin America Recombinant Human EGF 麻豆原创 Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Recombinant Human EGF 麻豆原创 Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Recombinant Human EGF 麻豆原创 Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Recombinant Human EGF 麻豆原创 Size by Country
10.4.1 Middle East, Africa, and Latin America Recombinant Human EGF 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Recombinant Human EGF 麻豆原创 Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Recombinant Human EGF 麻豆原创 Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 FUJIFILM Irvine Scientific
11.1.1 FUJIFILM Irvine Scientific Company Details
11.1.2 FUJIFILM Irvine Scientific Business Overview
11.1.3 FUJIFILM Irvine Scientific Recombinant Human EGF Introduction
11.1.4 FUJIFILM Irvine Scientific Revenue in Recombinant Human EGF Business (2019-2024)
11.1.5 FUJIFILM Irvine Scientific Recent Developments
11.2 PeproTech, Inc
11.2.1 PeproTech, Inc Company Details
11.2.2 PeproTech, Inc Business Overview
11.2.3 PeproTech, Inc Recombinant Human EGF Introduction
11.2.4 PeproTech, Inc Revenue in Recombinant Human EGF Business (2019-2024)
11.2.5 PeproTech, Inc Recent Developments
11.3 R&D Systems (Bio-Techne)
11.3.1 R&D Systems (Bio-Techne) Company Details
11.3.2 R&D Systems (Bio-Techne) Business Overview
11.3.3 R&D Systems (Bio-Techne) Recombinant Human EGF Introduction
11.3.4 R&D Systems (Bio-Techne) Revenue in Recombinant Human EGF Business (2019-2024)
11.3.5 R&D Systems (Bio-Techne) Recent Developments
11.4 Miltenyi Biotec
11.4.1 Miltenyi Biotec Company Details
11.4.2 Miltenyi Biotec Business Overview
11.4.3 Miltenyi Biotec Recombinant Human EGF Introduction
11.4.4 Miltenyi Biotec Revenue in Recombinant Human EGF Business (2019-2024)
11.4.5 Miltenyi Biotec Recent Developments
11.5 Thermo Fisher Scientific
11.5.1 Thermo Fisher Scientific Company Details
11.5.2 Thermo Fisher Scientific Business Overview
11.5.3 Thermo Fisher Scientific Recombinant Human EGF Introduction
11.5.4 Thermo Fisher Scientific Revenue in Recombinant Human EGF Business (2019-2024)
11.5.5 Thermo Fisher Scientific Recent Developments
11.6 Abcam PLC
11.6.1 Abcam PLC Company Details
11.6.2 Abcam PLC Business Overview
11.6.3 Abcam PLC Recombinant Human EGF Introduction
11.6.4 Abcam PLC Revenue in Recombinant Human EGF Business (2019-2024)
11.6.5 Abcam PLC Recent Developments
11.7 BioLegend Way
11.7.1 BioLegend Way Company Details
11.7.2 BioLegend Way Business Overview
11.7.3 BioLegend Way Recombinant Human EGF Introduction
11.7.4 BioLegend Way Revenue in Recombinant Human EGF Business (2019-2024)
11.7.5 BioLegend Way Recent Developments
11.8 STEMCELL Technologies
11.8.1 STEMCELL Technologies Company Details
11.8.2 STEMCELL Technologies Business Overview
11.8.3 STEMCELL Technologies Recombinant Human EGF Introduction
11.8.4 STEMCELL Technologies Revenue in Recombinant Human EGF Business (2019-2024)
11.8.5 STEMCELL Technologies Recent Developments
11.9 Eurofins DiscoverX
11.9.1 Eurofins DiscoverX Company Details
11.9.2 Eurofins DiscoverX Business Overview
11.9.3 Eurofins DiscoverX Recombinant Human EGF Introduction
11.9.4 Eurofins DiscoverX Revenue in Recombinant Human EGF Business (2019-2024)
11.9.5 Eurofins DiscoverX Recent Developments
11.10 RayBiotech, Inc
11.10.1 RayBiotech, Inc Company Details
11.10.2 RayBiotech, Inc Business Overview
11.10.3 RayBiotech, Inc Recombinant Human EGF Introduction
11.10.4 RayBiotech, Inc Revenue in Recombinant Human EGF Business (2019-2024)
11.10.5 RayBiotech, Inc Recent Developments
11.11 Prospec-Tany
11.11.1 Prospec-Tany Company Details
11.11.2 Prospec-Tany Business Overview
11.11.3 Prospec-Tany Recombinant Human EGF Introduction
11.11.4 Prospec-Tany Revenue in Recombinant Human EGF Business (2019-2024)
11.11.5 Prospec-Tany Recent Developments
11.12 Tonbo Biosciences
11.12.1 Tonbo Biosciences Company Details
11.12.2 Tonbo Biosciences Business Overview
11.12.3 Tonbo Biosciences Recombinant Human EGF Introduction
11.12.4 Tonbo Biosciences Revenue in Recombinant Human EGF Business (2019-2024)
11.12.5 Tonbo Biosciences Recent Developments
11.13 EnQuire Bio
11.13.1 EnQuire Bio Company Details
11.13.2 EnQuire Bio Business Overview
11.13.3 EnQuire Bio Recombinant Human EGF Introduction
11.13.4 EnQuire Bio Revenue in Recombinant Human EGF Business (2019-2024)
11.13.5 EnQuire Bio Recent Developments
11.14 ScienCell Research Laboratories
11.14.1 ScienCell Research Laboratories Company Details
11.14.2 ScienCell Research Laboratories Business Overview
11.14.3 ScienCell Research Laboratories Recombinant Human EGF Introduction
11.14.4 ScienCell Research Laboratories Revenue in Recombinant Human EGF Business (2019-2024)
11.14.5 ScienCell Research Laboratories Recent Developments
11.15 BioVision, Inc
11.15.1 BioVision, Inc Company Details
11.15.2 BioVision, Inc Business Overview
11.15.3 BioVision, Inc Recombinant Human EGF Introduction
11.15.4 BioVision, Inc Revenue in Recombinant Human EGF Business (2019-2024)
11.15.5 BioVision, Inc Recent Developments
11.16 Abm Inc
11.16.1 Abm Inc Company Details
11.16.2 Abm Inc Business Overview
11.16.3 Abm Inc Recombinant Human EGF Introduction
11.16.4 Abm Inc Revenue in Recombinant Human EGF Business (2019-2024)
11.16.5 Abm Inc Recent Developments
11.17 Cell Guidance Systems
11.17.1 Cell Guidance Systems Company Details
11.17.2 Cell Guidance Systems Business Overview
11.17.3 Cell Guidance Systems Recombinant Human EGF Introduction
11.17.4 Cell Guidance Systems Revenue in Recombinant Human EGF Business (2019-2024)
11.17.5 Cell Guidance Systems Recent Developments
11.18 Creative BioMart
11.18.1 Creative BioMart Company Details
11.18.2 Creative BioMart Business Overview
11.18.3 Creative BioMart Recombinant Human EGF Introduction
11.18.4 Creative BioMart Revenue in Recombinant Human EGF Business (2019-2024)
11.18.5 Creative BioMart Recent Developments
11.19 Sino Biological
11.19.1 Sino Biological Company Details
11.19.2 Sino Biological Business Overview
11.19.3 Sino Biological Recombinant Human EGF Introduction
11.19.4 Sino Biological Revenue in Recombinant Human EGF Business (2019-2024)
11.19.5 Sino Biological Recent Developments
11.20 Cell Sciences
11.20.1 Cell Sciences Company Details
11.20.2 Cell Sciences Business Overview
11.20.3 Cell Sciences Recombinant Human EGF Introduction
11.20.4 Cell Sciences Revenue in Recombinant Human EGF Business (2019-2024)
11.20.5 Cell Sciences Recent Developments
11.21 Axol Bioscience
11.21.1 Axol Bioscience Company Details
11.21.2 Axol Bioscience Business Overview
11.21.3 Axol Bioscience Recombinant Human EGF Introduction
11.21.4 Axol Bioscience Revenue in Recombinant Human EGF Business (2019-2024)
11.21.5 Axol Bioscience Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
FUJIFILM Irvine Scientific
PeproTech, Inc
R&D Systems (Bio-Techne)
Miltenyi Biotec
Thermo Fisher Scientific
Abcam PLC
BioLegend Way
STEMCELL Technologies
Eurofins DiscoverX
RayBiotech, Inc
Prospec-Tany
Tonbo Biosciences
EnQuire Bio
ScienCell Research Laboratories
BioVision, Inc
Abm Inc
Cell Guidance Systems
Creative BioMart
Sino Biological
Cell Sciences
Axol Bioscience
听
听
*If Applicable.
